Cargando…
Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study
BACKGROUND: Genomic profiling of cerebrospinal fluid (CSF) can be used to detect actionable mutations and guide clinical treatment of non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Examining the performance of CSF samples in real-world settings can confirm...
Autores principales: | Shen, Fangfang, Liang, Naixin, Fan, Zaiwen, Zhao, Min, Kang, Jing, Wang, Xifang, Hu, Qun, Mu, Yongping, Wang, Kai, Yuan, Mingming, Chen, Rongrong, Guo, Wei, Dong, Guilan, Zhao, Jun, Bai, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259993/ https://www.ncbi.nlm.nih.gov/pubmed/35814426 http://dx.doi.org/10.3389/fonc.2022.889591 |
Ejemplares similares
-
Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022) -
Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC
por: Li, Yilin, et al.
Publicado: (2023) -
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
por: Boire, Adrienne, et al.
Publicado: (2019) -
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023) -
Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
por: Yan, Weiwei, et al.
Publicado: (2020)